BPMC 250117 80.00C (BPMC250117C80000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

BPMC250117C80000

Watchlist

9.11
-32.49-78.10%

15min DelayClose Jan 10 16:00 ET

9.11High9.11Low

Intraday

5D
Daily

News

Barclays Reaffirms Their Hold Rating on Blueprint Medicines (BPMC)
TipRanksJan 9 03:55 ET · Ratings
Stifel Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Maintains Target Price $155
Moomoo NewsJan 7 08:31 ET · Ratings
Stifel Nicolaus Sticks to Its Buy Rating for Blueprint Medicines (BPMC)
TipRanksJan 7 07:45 ET · Ratings
J.P. Morgan Maintains Blueprint Medicines(BPMC.US) With Buy Rating
Moomoo NewsJan 6 07:31 ET · Ratings
J.P. Morgan Sticks to Its Buy Rating for Blueprint Medicines (BPMC)
TipRanksJan 6 06:38 ET · Ratings
Those Who Invested in Blueprint Medicines (NASDAQ:BPMC) Five Years Ago Are up 17%
Simply Wall StJan 6 05:10 ET

Comments

Stock_Drift

Apr 11, 2024 20:13

Extended Hours Top Moovers.

$Gryphon Digital Mining (GRYP.US)$ $Zimmer Biomet Holdings (ZBH.US)$ $Cohu Inc (COHU.US)$ $Evolv Technologies (EVLV.US)$ $Brookfield (BN.US)$ $VACASA INC (VCSA.US)$ $Blueprint Medicines (BPMC.US)$ $Williams-Sonoma (WSM.US)$ $U.S. Century Bank (USCB.US)$
📊⚡️📊

frankinglily

Apr 1, 2024 03:50

Updated Complete & Utter M&A Guesses Purely for Entertainment Purposes:

$SPDR S&P Biotech ETF (XBI.US)$
$Merck & Co (MRK.US)$ x $Immunovant (IMVT.US)$
$Eli Lilly and Co (LLY.US)$ x $Cytokinetics (CYTK.US)$ (and soon)
$Regeneron Pharmaceuticals (REGN.US)$ x $Apellis Pharmaceuticals (APLS.US)$ (panache & brash)
$Gilead Sciences (GILD.US)$ x % $Madrigal Pharmaceuticals (MDGL.US)$ (liver king)
$Bristol-Myers Squibb (BMY.US)$ x $Iovance Biotherapeutics (IOVA.US)$ (cell Tx boost needed)
$Eli Lilly and Co (LLY.US)$ x $Merus (MRUS.US)$ (partner n...

Moomoo AI

Mar 15, 2024 06:44

Insiders selling shares without any recorded purchases over the last year raises caution. The alignment between management and smaller shareholders due to insider ownership is not outstanding. Caution is advised before buying shares in Blueprint Medicines due to significant selling activity.

Possible Bearish Signals With Blueprint Medicines Insiders Disposing Stock

Moomoo AI

Feb 19, 2024 12:10

The stock's commendable performance is tied to revenue growth. However, profitability and cash flow checks are crucial for future views. Given the strong share price momentum, the stock warrants a closer look.

Blueprint Medicines (NASDAQ:BPMC) Delivers Shareholders Decent 95% Return Over 1 Year, Surging 16% in the Last Week Alone

Moomoo AI

Jan 29, 2024 09:59

Blueprint Medicines' high P/S ratio is worrisome due to its lower projected growth compared to the broader industry. If future revenues don't support this optimism, the current high P/S ratio may not be sustainable. Prices may not be reasonable unless conditions significantly improve.

Blueprint Medicines Corporation's (NASDAQ:BPMC) Shareholders Might Be Looking For Exit